Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

How "immunomodulatory" are IMIDs?

In this issue of Blood, Hsu and colleagues report that the immunostimulatory effect of lenalidomide on natural killer (NK)–cell function is profoundly suppressed by concurrent dexamethasone (Dex) therapy in multiple myeloma (MM) patients. These results could have major implications for the design of clinical trials combining lenalidomide and immunotherapies with the intent to stimulate the anti...

Drugs Used in Neurodegenerative Disorders

Neurodegenerative diseases are a group of disorders characterized by neuronal loss and generally an accumulation of insoluble intracellular or extracellular material in certain brain regions. Most neurodegenerative disorders are of unknown etiology, affect the elderly, are progressive, and damage selected neuronal populations or brain regions. There are some inherited forms of these disorders; ...

Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

Better the drugs you know than the drugs you do not know. Drug repurposing is a promising, fast, and cost effective method that can overcome traditional de novo drug discovery and development challenges of targeting neuropsychiatric and other disorders. Drug discovery and development targeting neuropsychiatric disorders are complicated because of the limitations in understanding pathophysiologi...

Small Molecules: Therapeutic Application in Neuropsychiatric and Neurodegenerative Disorders.

In recent years, an increasing number of studies have been published, focusing on the potential therapeutic use of small catalytic agents with strong biological properties. So far, most of these works have only regarded specific clinical fields, such as oncology, infectivology and general pathology, in particular with respect to the treatment of significant inflammatory processes. However, inte...

Gut Microbiota and Neuropsychiatric Disorders